Cholangitis

Gilead Sciences’ oral therapy seladelpar has been conditionally approved by the European Commission as a second-line therapy for adults with primary biliary…

A second liver transplant results in transplant and patient outcomes in people with primary sclerosing cholangitis (PSC) that are comparable or better than those…

Four weeks of treatment with vancomycin, a common antibiotic, lowered  inflammatory bowel disease (IBD) in people with primary sclerosing cholangitis (PSC), data from a…

Testing positive for the self-reactive anti-gp210 and anti-centromeric antibodies significantly increases the risk of poor liver-related outcomes for people with primary biliary cholangitis (PBC),…

A predictive tool that incorporates several blood biomarkers may help to identify primary biliary cholangitis (PBC) patients who are less likely to respond to treatment…

Gilead Sciences’ Livdelzi (seladelpar) has been approved in the U.K. as a treatment for adults with primary biliary cholangitis (PBC), either in combination…

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to CNP-104, Cour Pharmaceuticals’ treatment candidate for primary biliary cholangitis (PBC).

Liver transplants from a living donor may mean a lower success and a higher need for a second transplant relative to those from a deceased…

A branch of the European Medicines Agency (EMA) has recommended that Gilead Sciences’ oral therapy seladelpar be approved in the European Union as a…

Sleep disorders affect about half of adults with primary biliary cholangitis (PBC), and are associated with more severe disease and worse outcomes, according to…